MM delivery study ends this week as Q3 comes to a close. The study was to determine what had better results, oral or rectal. I expect moving forward here for OWCP to keep this study as quite as possible. Giving away there methodology on this study moving forward would be a mistake. So I will continue to be patient for updates as the company deems necessary. This study for your longterm shares will pay dividends year over year as it progresses through the orphan drug stage.
News 
Market Data 
Discover 
